blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3165236

EP3165236 - METHODS FOR TREATING VISCERAL PAIN BY ADMINISTERING ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  20.01.2023
Database last updated on 29.06.2024
FormerThe patent has been granted
Status updated on  11.02.2022
FormerGrant of patent is intended
Status updated on  14.10.2021
FormerExamination is in progress
Status updated on  20.07.2018
FormerRequest for examination was made
Status updated on  10.11.2017
FormerThe application has been published
Status updated on  07.04.2017
Most recent event   Tooltip31.05.2024Lapse of the patent in a contracting state
New state(s): MK		published on 03.07.2024 [2024/27]
Applicant(s)For all designated states
Teva Pharmaceuticals International GmbH
Schlüsselstrasse 12
8645 Jona / CH
[2017/30]
Former [2017/19]For all designated states
Labrys Biologics Inc.
1700 Owens Street No. 595
San Francisco, CA 94158 / US
Inventor(s)01 / Pios, Ariel, Ates
Rinat Laboratories
230 East Grand Avenue
San Francisco, CA 94080 / US
02 / Poulsen, Kristian, Todd
Rinat Laboratories
230 East Grand Avenue
San Francisco, CA 94080 / US
03 / Shelton, David Louis
Rinat Laboratories
230 East Grand Avenue
San Francisco, CA 94080 / US
04 / Zeller, Joerg
Rinat Laboratories
230 East Grand Avenue
San Francisco, CA 94080 / US
 [2017/19]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2017/19]
Application number, filing date16202020.023.08.2010
[2017/19]
Priority number, dateUS2009023790128.08.2009         Original published format: US 237901
[2017/19]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3165236
Date:10.05.2017
Language:EN
[2017/19]
Type: B1 Patent specification 
No.:EP3165236
Date:16.03.2022
Language:EN
[2022/11]
Search report(s)(Supplementary) European search report - dispatched on:EP14.03.2017
ClassificationIPC:A61K39/395, C07K16/26
[2017/19]
CPC:
C07K16/26 (EP,KR,US); A61K39/395 (KR); C07K16/18 (EP,CN,US);
A61P1/00 (EP); A61P1/04 (EP); A61P1/14 (EP);
A61P1/18 (EP); A61P13/00 (EP); A61P13/08 (EP);
A61P13/10 (EP); A61P13/12 (EP); A61P15/00 (EP);
A61P15/04 (EP); A61P15/12 (EP); A61P25/00 (EP);
A61P25/04 (EP); A61P29/00 (EP); A61P9/08 (EP);
A61K2039/505 (EP,CN,US); C07K2317/55 (EP,CN,US); C07K2317/56 (EP,CN,US);
C07K2317/565 (EP,CN,US); C07K2317/76 (EP,CN,US); C07K2317/92 (EP,CN,US);
C07K2317/94 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2017/50]
Former [2017/19]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  SM,  TR 
TitleGerman:VERFAHREN ZUR BEHANDLUNG VON EINGEWEIDESCHMERZ MITTELS VERABREICHUNG VON ANTAGONISTISCHEN ANTIKÖRPERN GEGEN CALCITONINGEN-ASSOZIIERTES PEPTID[2017/19]
English:METHODS FOR TREATING VISCERAL PAIN BY ADMINISTERING ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE[2017/19]
French:PROCÉDÉS DE TRAITEMENT DE LA DOULEUR VISCÉRALE PAR ADMINISTRATION D'ANTICORPS D'ANTAGONISTES DIRIGÉS CONTRE UN PEPTIDE ASSOCIÉ AU GÈNE DE LA CALCITONINE[2017/19]
Biological materialThis application mentions deposited biological material, check the file for details
Examination procedure02.12.2016Date on which the examining division has become responsible
31.10.2017Examination requested  [2017/50]
21.02.2018Amendment by applicant (claims and/or description)
20.07.2018Despatch of a communication from the examining division (Time limit: M06)
05.02.2019Reply to a communication from the examining division
08.07.2019Despatch of a communication from the examining division (Time limit: M06)
14.02.2020Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
24.04.2020Reply to a communication from the examining division
29.10.2020Despatch of a communication from the examining division (Time limit: M04)
08.03.2021Reply to a communication from the examining division
15.10.2021Communication of intention to grant the patent
03.02.2022Fee for grant paid
03.02.2022Fee for publishing/printing paid
03.02.2022Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP10754584.0  / EP2470207
Opposition(s)19.12.2022No opposition filed within time limit [2023/08]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
24.04.2020Request for further processing filed
24.04.2020Full payment received (date of receipt of payment)
Request granted
06.05.2020Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
05.02.2019Request for further processing filed
05.02.2019Full payment received (date of receipt of payment)
Request granted
15.02.2019Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
21.02.2018Request for further processing filed
21.02.2018Full payment received (date of receipt of payment)
Request granted
05.03.2018Decision despatched
Fees paidRenewal fee
02.12.2016Renewal fee patent year 03
02.12.2016Renewal fee patent year 04
02.12.2016Renewal fee patent year 05
02.12.2016Renewal fee patent year 06
02.12.2016Renewal fee patent year 07
22.08.2017Renewal fee patent year 08
28.08.2018Renewal fee patent year 09
26.08.2019Renewal fee patent year 10
20.08.2020Renewal fee patent year 11
23.08.2021Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.08.2010
AL16.03.2022
AT16.03.2022
CY16.03.2022
CZ16.03.2022
DK16.03.2022
EE16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
MC16.03.2022
MK16.03.2022
PL16.03.2022
RO16.03.2022
SE16.03.2022
SI16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
IS16.07.2022
PT18.07.2022
IE23.08.2022
LU23.08.2022
BE31.08.2022
[2024/27]
Former [2024/21]HU23.08.2010
AL16.03.2022
AT16.03.2022
CY16.03.2022
CZ16.03.2022
DK16.03.2022
EE16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
MC16.03.2022
PL16.03.2022
RO16.03.2022
SE16.03.2022
SI16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
IS16.07.2022
PT18.07.2022
IE23.08.2022
LU23.08.2022
BE31.08.2022
Former [2024/18]HU23.08.2010
AL16.03.2022
AT16.03.2022
CZ16.03.2022
DK16.03.2022
EE16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
MC16.03.2022
PL16.03.2022
RO16.03.2022
SE16.03.2022
SI16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
IS16.07.2022
PT18.07.2022
IE23.08.2022
LU23.08.2022
BE31.08.2022
Former [2023/42]AL16.03.2022
AT16.03.2022
CZ16.03.2022
DK16.03.2022
EE16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
MC16.03.2022
PL16.03.2022
RO16.03.2022
SE16.03.2022
SI16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
IS16.07.2022
PT18.07.2022
IE23.08.2022
LU23.08.2022
BE31.08.2022
Former [2023/33]AL16.03.2022
AT16.03.2022
CZ16.03.2022
DK16.03.2022
EE16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
MC16.03.2022
PL16.03.2022
RO16.03.2022
SE16.03.2022
SI16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
IS16.07.2022
PT18.07.2022
IE23.08.2022
LU23.08.2022
Former [2023/21]AL16.03.2022
AT16.03.2022
CZ16.03.2022
DK16.03.2022
EE16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
MC16.03.2022
PL16.03.2022
RO16.03.2022
SE16.03.2022
SI16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
IS16.07.2022
PT18.07.2022
LU23.08.2022
Former [2023/16]AL16.03.2022
AT16.03.2022
CZ16.03.2022
DK16.03.2022
EE16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
MC16.03.2022
PL16.03.2022
RO16.03.2022
SE16.03.2022
SI16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
IS16.07.2022
PT18.07.2022
Former [2023/10]AL16.03.2022
AT16.03.2022
CZ16.03.2022
DK16.03.2022
EE16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
PL16.03.2022
RO16.03.2022
SE16.03.2022
SI16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
IS16.07.2022
PT18.07.2022
Former [2023/07]AL16.03.2022
AT16.03.2022
CZ16.03.2022
DK16.03.2022
EE16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
PL16.03.2022
RO16.03.2022
SE16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
IS16.07.2022
PT18.07.2022
Former [2023/01]AL16.03.2022
AT16.03.2022
CZ16.03.2022
EE16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
PL16.03.2022
RO16.03.2022
SE16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
IS16.07.2022
PT18.07.2022
Former [2022/51]AT16.03.2022
CZ16.03.2022
EE16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
PL16.03.2022
RO16.03.2022
SE16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
IS16.07.2022
PT18.07.2022
Former [2022/50]AT16.03.2022
CZ16.03.2022
EE16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
PL16.03.2022
RO16.03.2022
SE16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
PT18.07.2022
Former [2022/49]AT16.03.2022
CZ16.03.2022
EE16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
RO16.03.2022
SE16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
PT18.07.2022
Former [2022/48]AT16.03.2022
CZ16.03.2022
EE16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
RO16.03.2022
SE16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
PT18.07.2022
Former [2022/47]AT16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
RO16.03.2022
SE16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
PT18.07.2022
Former [2022/39]FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
SE16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
Former [2022/36]HR16.03.2022
LT16.03.2022
LV16.03.2022
SE16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
Former [2022/35]HR16.03.2022
LT16.03.2022
SE16.03.2022
BG16.06.2022
NO16.06.2022
Former [2022/33]LT16.03.2022
NO16.06.2022
Documents cited:Search[Y]EP1031350  (WARNER LAMBERT CO [US]) [Y] 2-7 * the whole document *;
 [Y]WO2006077212  (EURO CELTIQUE SA [LU], et al) [Y] 2-7 * the whole document *;
 [Y]WO2007025212  (WEX PHARMACEUTICALS INC [CA], et al) [Y] 2-7 * the whole document *;
 [Y]WO2007054809  (RINAT NEUROSCIENCE CORP [US], et al) [Y] 1-18 * the whole document *;
 [Y]WO2007076336  (LILLY CO ELI [US], et al) [Y] 1-18 * the whole document *;
 [Y]  - DELAFOY L ET AL, "Interactive involvement of brain derived neurotrophic factor, nerve growth factor, and calcitonin gene related peptide in colonic hypersensitivity in the rat.", GUT JUL 2006 LNKD- PUBMED:16401692, (200607), vol. 55, no. 7, ISSN 0017-5749, pages 940 - 945, XP002606934 [Y] 1-18 * the whole document *

DOI:   http://dx.doi.org/10.1136/GUT.2005.064063
 [YD]  - JULIA V ET AL, "Tachykininergic mediation of viscerosensitive responses to acute inflammation in rats: role of CGRP.", THE AMERICAN JOURNAL OF PHYSIOLOGY JAN 1997 LNKD- PUBMED:9038887, (199701), vol. 272, no. 1 Pt 1, ISSN 0002-9513, pages G141 - G146, XP009140476 [YD] 1-18 * the whole document *
 [Y]  - ZELLER J ET AL, "CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat", BRITISH JOURNAL OF PHARMACOLOGY, (200812), vol. 155, no. 7, ISSN 0007-1188, pages 1093 - 1103, XP002606936 [Y] 1-18 * the whole document *

DOI:   http://dx.doi.org/10.1038/BJP.2008.334
 [Y]  - WONG H C ET AL, "MONOCLONAL ANTIBODY TO RAT ALPHA-CGRP: PRODUCTION, CHARACTERIZATION, AND IN VIVO IMMUNONEUTRALIZATION ACTIVITY", HYBRIDOMA, LIEBERT, NEW YORK, NY, US, (19930101), vol. 12, no. 1, ISSN 0272-457X, pages 93 - 106, XP009082532 [Y] 1-18 * the whole document *
 [Y]  - KURAISHI Y ET AL, "Antinociception induced in rats by intrathecal administration of antiserum against calcitonin gene-related peptide", NEUROSCIENCE LETTERS, LIMERICK, IE LNKD- DOI:10.1016/0304-3940(88)90611-8, vol. 92, no. 3, ISSN 0304-3940, (19881017), pages 325 - 329, (19881017), XP024374377 [Y] 1-18 * the whole document *

DOI:   http://dx.doi.org/10.1016/0304-3940(88)90611-8
 [Y]  - KAWAMURA M ET AL, "Antinociceptive effect of intrathecally administered antiserum against calcitonin gene-related peptide on thermal and mechanical noxious stimuli in experimental hyperalgesic rats", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/0006-8993(89)90990-6, vol. 497, no. 1, ISSN 0006-8993, (19890911), pages 199 - 203, (19890911), XP024272914 [Y] 1-18 * the whole document *

DOI:   http://dx.doi.org/10.1016/0006-8993(89)90990-6
 [A]  - BENNETT ADRIANNE D ET AL, "Alleviation of mechanical and thermal allodynia by CGRP8-37 in a rodent model of chronic central pain", PAIN, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL LNKD- DOI:10.1016/S0304-3959(00)00242-6, (20000501), vol. 86, no. 1-2, ISSN 0304-3959, pages 163 - 175, XP002536470 [A] 1-18 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0304-3959(00)00242-6
Examination   - RECOBER ANA ET AL, "Calcitonin gene-related peptide: an update on the biology", CURRENT OPINION IN NEURO, RAPID SCIENCE PUBLISHERS, LONDON, GB, (20090601), vol. 22, no. 3, doi:10.1097/WCO.0B013E32832B2427, ISSN 1350-7540, pages 241 - 246, XP008119807

DOI:   http://dx.doi.org/10.1097/WCO.0b013e32832b2427
    - VIZZARD ET AL, "Alterations in neuropeptide expression in lumbosacral bladder pathways following chronic cystitis", JOURNAL OF CHEMICAL NEUROANATOMY, CHICHESTER, GB, vol. 21, no. 2, ISSN 0891-0618, (20010301), pages 125 - 138, (20010301), XP027358580
by applicantUS4816567
 US5500362
 US5545807
 US5545806
 US5569825
 US5625126
 US5633425
 US5661016
 US5750373
 US5821337
 WO9958572
 WO2007054809
 WO2007076336
    - LONGSTRETH ET AL., GASTROENTEROLOGY, (2006), vol. 130, no. 5, pages 1480 - 91
    - AZIZ, GASTROENTEROLOGY, (2006), vol. 131, no. 2, pages 661 - 4
    - DELAFOY ET AL., GUT, (2006), vol. 55, no. 7, pages 940 - 5
    - GAY ET AL., NEUROIMMUNOMODULATION, (2006), vol. 13, no. 2, pages 114 - 121
    - ADAM ET AL., PAIN, (2006), vol. 123, no. 1-2, pages 179 - 86
    - LANCET, (1999), vol. 353, pages 2145 - 48
    - ADWANIKAR ET AL., PAIN, (2007), vol. 132, no. 1-2, pages 53 - 66
    - PLOURDE ET AL., AM J PHYSIOL., (1997), vol. 273, pages G191 - 6
    - JULIA; BUENO, AM J PHYSIOL., (1997), vol. 272, pages G141 - 6
    - ., Methods in Molecular Biology, HUMANA PRESS
    - ., Methods in Enzymology, ACADEMIC PRESS, INC.
    - D.M. WEIR AND C.C. BLACKWELL,, Handbook of Experimental Immunology, D.M. WEIR AND C.C. BLACKWELL,
    - KOHLER; MILSTEIN, NATURE, (1975), vol. 256, page 495
    - MCCAFFERTY ET AL., NATURE, (1990), vol. 348, pages 552 - 554
    - VAUGHAN ET AL., NATURE BIOTECHNOLOGY, (1996), vol. 14, pages 309 - 314
    - SHEETS ET AL., PNAS, (USA, (1998), vol. 95, pages 6157 - 6162
    - HOOGENBOOM; WINTER, J. MOL. BIOL., (1991), vol. 227, page 381
    - MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, page 581
    - COLE ET AL., Monoclonal Antibodies and Cancer Therapy, ALAN R. LISS, (1985), page 77
    - BOERNER ET AL., J. IMMUNOL., (1991), vol. 147, no. 1, pages 86 - 95
    - WONG HC ET AL., HYBRIDOMA, (1993), vol. 12, pages 93 - 106
    - AL-LAZIKANI ET AL., J. MOLEC. BIOL., (1997), vol. 273, pages 927 - 948
    - RAVETCH; KINET, ANN. REV. IMMUNOL., (1991), vol. 9, pages 457 - 92
    - CAPEL ET AL., IMMUNOMETHODS, (1994), vol. 4, pages 25 - 34
    - DE HAAS ET AL., J. LAB. CLIN. MED., (1995), vol. 126, pages 330 - 41
    - GUYER ET AL., J. IMMUNOL., (1976), vol. 117, page 587
    - KIM ET AL., J. IMMUNOL., (1994), vol. 24, page 249
    - GAZZANO-SANTORO ET AL., J. IMMUNOL. METHODS, (1996), vol. 202, page 163
    - CLYNES ET AL., PNAS (USA, (1998), vol. 95, pages 652 - 656
    - KATZ ET AL., SURG CLIN NORTH AM.,, (1999), vol. 79, no. 2, pages 231 - 52
    - CARACENI ET AL., J PAIN SYMPTOM MANAGE, (2002), vol. 23, no. 3, pages 239 - 55
    - DROSSMAN ET AL., DIGESTIVE DISEASES AND SCIENCES, (1995), vol. 40, no. 5, pages 986 - 995
    - FRANCIS ET AL., ALIMENT PHARMACOL THER., (1997), vol. 11, no. 2, pages 395 - 402
    - TAN ET AL., CLIN. SCI. (LOND, (1995), vol. 89, pages 565 - 73
    - PLOURDE ET AL., PEPTIDES, (1993), vol. 14, pages 1225 - 1229
    - EUR. J. IMMUNOL., (1999), vol. 29, pages 2613 - 2624
 WO2009IB50849
 WO2009IB50852
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.